|Corporate Overview History Partners
Co-Founder, Chairman, and CSO
Dr. Wolfgang Schatton co-founded KliniPharm in 1993 to address the lack of technologically innovative natural products based on the latest scientific research. His distinguished career in the pharmaceutical industry includes over 15 years as head of R&D at Merz Pharmaceuticals and Pascoe Naturmedizin and a successful track record for developing and bringing drugs to the market. Dr. Schatton has been responsible for numerous pharmaceutical product approvals and new product launches in the fields of tumor angiogenesis, infectious, cardiovascular, and neurodegenerative disease - most notably the multi-billion dollar blockbuster Namenda™ (Axura®, Memantine) while Head of R&D at Merz. His expertise in scientific research, managerial planning, and development and manufacturing of pharmaceuticals from all-natural bioactive ingredients has been a tremendous asset to KliniPharm.
Dr. Schatton earned his doctoral degree in Pharmacology and Medicinal Chemistry from the University of Frankfurt, Germany. He has held several academic appointments as an adjunct professor, has led numerous research projects, and authored over 30 scholarly articles and patents. His ties to industry and academia have been instrumental in forming collaborations with corporate partners and scientific institutions throughout the European Union, from which KliniPharm’s patents, product prototypes, and product developments have emerged.
Co-Founder and CEO
Mrs. Schatton co-founded KliniPharm with Dr. Wolfgang Schatton in 1993. With over ten years of experience in project planning and coordination with Greek governmental organizations, she has been instrumental in providing strategic vision for KliniPharm’s growth, setting up international partnerships between Greece, Germany, and scientific institutes throughout Europe, and facilitating the establishment of KliniPharm’s sustainable sponge farms. Mrs. Schatton was recognized by the Greek-German Economic Association in 2003 for her strategic leadership in advancing economic relations between Greece and Germany and helping further the progress of marine research. She continues to drive KliniPharm’s growth through expansion initiatives with corporate partners, academic institutions, and European governmental organizations.
Mrs. Schatton graduated in International Relations from Pantios University, Athens, Greece, and received postgraduate training in Political Science at the Collège de Sorbonne in Paris, France, and the University of Frankfurt, Germany.
Partner and Scientific Advisor
Dr. Tobias Schatton joined KliniPharm in 2001 and has focused on the strategic positioning of KliniPharm’s R&D activities, coordination with academic and corporate partners, and development of the product portfolio. He has been a prime mover of eleana™, KliniPharm’s skin care and wellness line. Dr. Schatton has expertise in drug delivery research as well as basic and translational scientific research with a specific emphasis on skin-associated stem cells and their role in immunity, tissue regeneration, and tumor development.
Dr. Schatton holds a Pharm.D. degree from the University of Frankfurt, Germany, and a Ph.D. degree in Biochemistry from the University of Würzburg, Germany, based on research conducted during a Research Fellowship at Harvard Medical School. He is currently a Faculty Member of Harvard Medical School and a Research Associate of the Department of Dermatology at Brigham and Women’s Hospital , Boston, MA, USA. He has been the recipient of numerous awards, fellowships, and research grants and has published articles in leading scientific journals, including Nature.
Dr. Nikoletta Fotaki serves as a scientific advisor to KliniPharm and has been instrumental in providing expertise related to innovative drug delivery technologies. In particular, her knowledge of in vitro screening tools and related applications for predicting absorption in humans in order to optimize in vivo bioavailability during the early stages of drug formulation has proven invaluable to KliniPharm's development of novel products.
Dr. Fotaki is a UK-registered Greek Pharmacist. She holds a degree in Pharmacy and a Ph.D. in Biopharmaceutics-Pharmacokinetics, both from the National and Kapodistrian University of Athens, Greece, and a M.Sc. in Toxicology from the University of Surrey in the UK. She is currently a lecturer in Pharmaceutics in the Department of Pharmacy and Pharmacology at the University of Bath in the UK. She completed postdoctoral training at the School of Pharmacy at the University of Athens and at Roche Pharmaceuticals in the United States (New Jersey), where she supported innovation research for drug discovery and development. Dr. Fotaki has also held positions with the National Organization for Medicines in Greece. She has prominently contributed to several research projects and authored papers in leading scientific journals.
Dr. Jennifer Lin serves as medical advisor to KliniPharm, providing counsel on dermatologic conditions and anti-aging processes of the skin. Her clinical and research interests include sun- and aging-induced skin damage and skin cancer prevention. Her intuitive understanding of what patients want for their skin has been instrumental to the development of KliniPharm's all natural eleana™ skin care line.
Dr. Lin is a board-certified US dermatologist and faculty member of the Department of Dermatology at Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA. She completed her dermatology residency at the Harvard Combined Program, received her M.D. Degree from Harvard Medical School, and a B.A. from Harvard University. She received additional postgraduate training at the Wellman Center for Photomedicine, studying novel techniques using lasers to improve scars. Clinically, she sees patients with various dermatologic conditions and is involved with basic science and translational research in both wound healing and melanoma.
Jan Lennertz serves as business advisor to KliniPharm providing advice in areas such as marketing strategy, finances or collaboration strategy and has been an important sounding board to KliniPharm.
Mr. Lennertz holds a Diplom Kaufmann (MBA equivalent) from the European Business School, Oestrich-Winkel, Germany, as well as a Master of Business Administration from the University of Pittsburgh, USA. He is currently an Executive Director in Morgan Stanley’s Mergers & Acquisitions Department in New York. During his career at Morgan Stanley, he has also worked as a generalist in its Frankfurt, Germany office and as a member of the Consumer / Retail Industry Team in New York. He has advised on ~$150Bn in completed M&A and financing transactions across a variety of industries, including consumer, retail, and healthcare.
Copyright ©2002-2017 KliniPharm GmbH, Hauptstraße 10, 65760 Eschborn, Germany